Drug Profile
Research programme: PARP inhibitors - Eisai
Alternative Names: GPI 15427; GPI 18180; GPI 6000; Poly(ADP-ribose)-polymerase inhibitors research programme - MGI GPLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MGI GP
- Class Organic chemicals
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Hepatic fibrosis; Myocardial ischaemia; Stroke
- Discontinued Alzheimer's disease; Brain injuries; Parkinson's disease; Rheumatoid arthritis; Septic shock; Type 1 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 19 Feb 2010 Preclinical development is ongoing in Cancer
- 29 Jan 2008 Eisai acquires MGI PHARMA